An Open-Label Study Of Pregabalin In Subjects With Refractory Partial Seizures

Summary

The main purpose of this trial is to allow continued access to pregabalin to Canadian subjects who participated in global pregabalin epilepsy studies 1008-010; 1008-035; 1008-114 and 1008-164 and to continue to study the long term safety of pregabalin administered as adjunctive therapy at dosages from 150 mg/day to 600 mg/day in Canadian subjects with refractory partial seizures.

Timeline

Start

2007-03

Primary completion

2011-10

Completion

2011-10

Outcome

Outcome not reported

Stopped: “This study was terminated on April 8, 2011 as Pfizer Canada could no longer supply study drug. No efficacy or safety concerns factored into this decision.”

Drugs

Indications